Icon Plc $ICLR Shares Purchased by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC raised its position in Icon Plc (NASDAQ:ICLR) by 53.1% during the first quarter, Holdings Channel reports. The firm owned 36,659 shares of the medical research company’s stock after buying an additional 12,717 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Icon were worth $4,057,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of ICLR. Toth Financial Advisory Corp acquired a new stake in shares of Icon in the fourth quarter valued at $27,000. EFG International AG acquired a new position in Icon during the 4th quarter worth about $27,000. Ameriflex Group Inc. purchased a new position in Icon during the 3rd quarter valued at about $33,000. Abound Financial LLC purchased a new position in Icon during the 4th quarter valued at about $54,000. Finally, Johnson Financial Group Inc. acquired a new position in Icon in the 3rd quarter valued at about $71,000. 95.61% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ICLR has been the topic of several research reports. Royal Bank Of Canada raised shares of Icon from a “sector perform” rating to an “outperform” rating and increased their price target for the stock from $126.00 to $185.00 in a research report on Thursday, June 25th. JPMorgan Chase & Co. lifted their price objective on shares of Icon from $130.00 to $155.00 and gave the company a “neutral” rating in a report on Thursday, June 25th. Mizuho upped their target price on shares of Icon from $180.00 to $190.00 and gave the stock an “outperform” rating in a research note on Friday, June 26th. TD Cowen raised their price target on shares of Icon from $164.00 to $197.00 and gave the company a “buy” rating in a research report on Thursday, June 25th. Finally, Citigroup boosted their price target on shares of Icon from $140.00 to $165.00 and gave the stock a “neutral” rating in a research note on Thursday, June 25th. Nine investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $173.19.

Icon Stock Down 1.4%

Shares of ICLR traded down $2.33 during midday trading on Tuesday, hitting $168.61. The company had a trading volume of 32,549 shares, compared to its average volume of 1,502,293. Icon Plc has a 1 year low of $66.57 and a 1 year high of $211.00. The firm has a market capitalization of $12.91 billion, a P/E ratio of 30.07, a P/E/G ratio of 8.49 and a beta of 1.22. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.14 and a current ratio of 1.14. The company’s 50-day simple moving average is $136.63 and its 200-day simple moving average is $137.46.

Icon (NASDAQ:ICLR) last released its earnings results on Tuesday, June 23rd. The medical research company reported $2.50 earnings per share for the quarter, topping analysts’ consensus estimates of $2.43 by $0.07. The firm had revenue of $2.03 billion for the quarter, compared to analyst estimates of $1.98 billion. Icon had a net margin of 5.35% and a return on equity of 8.73%. The business’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.43 earnings per share. As a group, sell-side analysts expect that Icon Plc will post 9.43 EPS for the current year.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.